The potentiation of IFN-γ and induction of cytotoxic proteins by pegylated IL-10 in human CD8 T cells

Journal of Interferon and Cytokine Research

Volumn 35, Issue 12, 2015, Pages 948-955

  Chan, Ivan Ho ^a   Wu, Victoria ^a   Bilardello, Melissa ^a   Mar, Elliot ^a,b   Oft, Martin ^a   Van Vlasselaer, Peter ^a   Mumm, John Brian ^a  

^a ARMO Biosciences   (United States)

^b ValidPath   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC FACTOR; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEGYLATED RECOMBINANT HUMAN INTERLEUKIN 10; PERFORIN; RECOMBINANT INTERLEUKIN 10; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; GRANZYME; INTERLEUKIN 10; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ARTICLE; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL ISOLATION; DRUG EFFECT; DRUG USE; HUMAN; HUMAN CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SECRETION; BIOSYNTHESIS; CYTOTOXICITY; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; PERFORIN; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84951764428     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0221     Document Type: Article

References (27)

1. Adris S, Klein S, Jasnis M, Chuluyan E, Ledda M, Bravo A, Carbone C, Chernajovsky Y, Podhajcer O. 1999. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther 6(10):1705-1712.
2. Berman RM, Suzuki T, Tahara H, Robbins PD, Narula SK, Lotze MT. 1996. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 157(1):231-238.
3. Bhattacharyya S, Sen P, Wallet M, Long B, Baldwin AS, Jr., Tisch R. 2004. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood 104(4):1100-1109.
4. Cai G, Kastelein RA, Hunter CA. 1999. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol 29(9):2658-2665.
5. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. 1993. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 178(6):2207-2211.
6. Chernoff AE, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, Kennedy JS, Rabson AR, Wolff SM, Dinarello CA. 1995. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154(10):5492-5499.
7. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. 1991a. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174(5):1209-1220.
8. de Waal Malefyt R, Haanen J, Spits H, Roncarolo MG, te Velde A, Figdor C, Johnson K, Kastelein R, Yssel H, de Vries JE. 1991b. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 174(4):915-924.
9. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. 1993. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 151(3):1224-1234.
10. Emmerich J, Mumm JB, Chan IH, LaFace D, Truong H, McClanahan T, Gorman DM, Oft M. 2012. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 72(14):3570-3581.
11. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. 1991a. IL-10 inhibits cytokine production by activated macrophages. J Immunol 147(11):3815-3822.
12. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, OGarra A. 1991b. IL-10 acts on the antigenpresenting cell to inhibit cytokine production by Th1 cells. J Immunol 146(10):3444-3451.
13. Franklin RA, Tordai A, Patel H, Gardner AM, Johnson GL, Gelfand EW. 1994. Ligation of the T cell receptor complex results in activation of the Ras/Raf-1/MEK/MAPK cascade in human T lymphocytes. J Clin Invest 93(5):2134-2140.
14. Gerard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M, Velu T. 1996. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 7(1):23-31.
15. Groux H, Bigler M, de Vries JE, Roncarolo MG. 1996. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells. J Exp Med 184(1):19-29.
16. Groux H, Bigler M, de Vries JE, Roncarolo MG. 1998. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 160(7):3188-3193.
17. Harhaj EW, Maggirwar SB, Good L, Sun SC. 1996. CD28 mediates a potent costimulatory signal for rapid degradation of IkappaBbeta which is associated with accelerated activation of various NF-kappaB/Rel heterodimers. Mol Cell Biol 16(12):6736-6743.
18. Hurme M, Henttinen T, Karppelin M, Varkila K, Matikainen S. 1994. Effect of interleukin-10 on NF-kB and AP-1 activities in interleukin-2 dependent CD8 T lymphoblasts. Immunol Lett 42(3):129-133.
19. Lauw FN, Pajkrt D, Hack CE, Kurimoto M, van Deventer SJ, van der Poll T. 2000. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 165(5):2783-2789.
20. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ, Ryan JL. 1997. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90(7):2541-2548.
21. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale A, Eroshkin A, Aaronson S, Ronai Z. 2007. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell 11(5):447-460.
22. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765.
23. Mumm JB, Emmerich J, Zhang X, Chan I, Wu L, Mauze S, Blaisdell S, Basham B, Dai J, Grein J, Sheppard C, Hong K, Cutler C, Turner S, LaFace D, Kleinschek M, Judo M, Ayanoglu G, Langowski J, Gu D, Paporello B, Murphy E, Sriram V, Naravula S, Desai B, Medicherla S, Seghezzi W, McClanahan T, Cannon-Carlson S, Beebe AM, Oft M. 2011. IL-10 elicits IFNg-dependent tumor immune surveillance. Cancer Cell 20(6):781-796.
24. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Roman JJ, Parham GP, Cannon MJ. 2000. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol 74(10):4729-4737.
25. Schwartz RN, Stover L, Dutcher J. 2002. Managing toxicities of high-dose interleukin-2. Oncology (Williston Park) 16(11 Suppl 13):11-20.
26. Wang P, Wu P, Siegel MI, Egan RW, Billah MM. 1995. Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms. J Biol Chem 270(16):9558-9563.
27. Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z, Rong H, Chen J, Wang XY, Catino JJ, King I. 1996. Interleukin-10 inhibits tumor metastasis through an NK celldependent mechanism. J Exp Med 184(2):579-584.